1341209-23-1

Basic information

• Product Name: [(3R,3aS)-7-morpholino-1-oxo-1,3,3a,4-tetrahydrobenzo[b]oxazolo[3,4-d][1,4]oxazin-3-yl]methyl 3-nitrobenzene-1-sulfonate
• Synonyms: [(3R,3aS)-7-morpholino-1-oxo-1,3,3a,4-tetrahydrobenzo[b]oxazolo[3,4-d][1,4]oxazin-3-yl]methyl 3-nitrobenzene-1-sulfonate
• CAS NO: 1341209-23-1
• Molecular Weight: 491.478
• Mol File: 1341209-23-1.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: [(3R,3aS)-7-morpholino-1-oxo-1,3,3a,4-tetrahydrobenzo[b]oxazolo[3,4-d][1,4]oxazin-3-yl]methyl 3-nitrobenzene-1-sulfonate(CAS DataBase Reference)
• NIST Chemistry Reference: [(3R,3aS)-7-morpholino-1-oxo-1,3,3a,4-tetrahydrobenzo[b]oxazolo[3,4-d][1,4]oxazin-3-yl]methyl 3-nitrobenzene-1-sulfonate(1341209-23-1)
• EPA Substance Registry System: [(3R,3aS)-7-morpholino-1-oxo-1,3,3a,4-tetrahydrobenzo[b]oxazolo[3,4-d][1,4]oxazin-3-yl]methyl 3-nitrobenzene-1-sulfonate(1341209-23-1)

Safety Data

• Hazardous Substances Data: 1341209-23-1(Hazardous Substances Data)

Upstream product

• 1341209-15-1 benzyl (2-(((2R,3S)-3-(hydroxymethyl)oxiran-2-yl)methoxy)-4-morpholinophenyl)carbamate 
• 1341209-13-9 (Z)-benzyl (2-(4-hydroxybut-2-enyloxy)-4-morpholinophenyl)carbamate 
• 1341209-11-7 (Z)-4-(2-(benzyloxycarbonylamino)-5-morpholinophenoxy)but-2-enyl propionate 
• 1341209-09-3 (Z)-4-(5-morpholino-2-nitrophenoxy)but-2-enyl propionate 
• 1341209-21-9 (3R,3aS)-3-(hydroxymethyl)-7-morpholino-3a,4-dihydrobenzo[b]oxazolo[3,4-d][1,4]oxazin-1(3H)-one 
• 121-51-7 3-nitrobenzenesulphonyl chloride 
• 1341209-19-5 (3R,3aS)-3-{[(tert-butyldimethylsilyl)oxy]methyl}-7-morpholino-3a,4-dihydrobenzo[b]oxazolo[3,4-d][1,4]oxazin-1(3H)-one 
• 1341209-17-3 benzyl (2-{[(2R,3S)-3-{[(tert-butyldimethylsilyl)oxy]methyl}oxiran-2-yl]methoxy}-4-(morpholin-4-yl)phenyl)carbamate 
• 911845-36-8 (2Z)-4-(5-bromo-2-nitrophenoxy)but-2-enyl propionate 

Relevant articles and documents

Design, synthesis, and structure-activity relationship studies of highly potent novel benzoxazinyl-oxazolidinone antibacterial agents

A series of novel benzoxazinyl-oxazolidinones bearing nonaromatic heterocycle or aryl groups were designed and synthesized. Their in vitro and in vivo antibacterial activities were investigated. Most of the (3S, 3aS) biaryl benzoxazinyl-oxazolidinones exhibited potent activity against Gram-positive pathogens. SAR trends were observed; a pyridyl C ring was preferable to other 5- or 6-member aryl C rings, while fluorine substitution on the B ring generated derivatives with reduced activity. Various substituent group positions on the pyridyl ring were also evaluated. The resulting compounds displayed excellent activity against linezolid-resistant strains. Compound 45 exhibited excellent in vitro activity, with a MIC value of 0.25-0.5 μg/mL against MRSA and an activity against linezolid-resistant strains of 8-16-fold higher potency than linezolid. In a MRSA systemic infection model, compound 45 displayed an ED 50 5.0 mg/kg, a potency that is nearly 3-fold better than that of linezolid. This compound also showed excellent pharmacokinetic profiles, with a half-life of more than 5 h as well as an oral bioavailability of 81% in rats.